Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey

 

escrs app advert

Posters

Search Title by author or title

Frequency of pseudoexfoliation syndrome and surgical complications among Portuguese patients submitted to cataract surgery: the Gaia eye study

Poster Details

First Author: F.Sousa Neves PORTUGAL

Co Author(s):    J. Braga   J. Cardoso da Costa   D. Meira   J. Sequeira   R. Varandas        

Abstract Details

Purpose:

The purpose of this study was to evaluate the frequency of pseudoexfoliation syndrome (PEX) in patients submitted to cataract surgery in the North of Portugal and the associated surgical complications.

Setting:

Department of Ophthalmology of Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal

Methods:

We performed a cross-sectional study of all patients undergoing cataract surgery between June 1st and December 31st 2016 in the Department of Ophthalmology of Centro Hospitalar Vila Nova de Gaia/Espinho. The presence of PEX and the intraoperative pupil diameter were registered, as well as the final position of the intraocular lens and the occurrence surgical complications.

Results:

During the study period, 1445 eyes were submitted to cataract surgery, of which 1373 (1167 patients) fulfilled the selection criteria. PEX was observed in 103 eyes (7.5%) of 88 patients (7.7%). The proportion of eyes with normal pupil dilation was 1297 (95.5%). This percentage differed from 96.1% to 73.8%, in eyes without and with PEX respectively (p<0.001). Surgical complications were found in 55 (4%) procedures; 37 eyes (2.9%) did not have PEX versus 18 eyes (17.5%) with PEX (p<0.001). Of 76 eyes with small pupil, 13.2% recorded intraoperative adverse events versus 3.5% with normal pupil size (p<0.001).

Conclusions:

Prevalence of PEX among patients submitted to cataract surgery in our reference centre in the north of Portugal was 7.7%. PEX was a very significant risk factor for surgical adverse events.

Financial Disclosure:

None

Back to Poster listing